search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
NEWS LABORATORY INFORMATICS


Agilent and Imperial College London agree collaboration


Agilent Technologies and Imperial College London have signed a strategic scientific collaboration agreement that brings together Agilent’s analytical technologies with Imperial researchers. Under the agreement, Agilent will support Imperial with a broad range of instruments to equip a new Agilent sponsored Measurement Suite. The Agilent Measurement Suite will be


housed within Imperial’s Molecular Sciences Research Hub at the new White City Campus due to open later this year.Scientists at Imperial will use the laboratory to extend their interdisciplinary research including fundamental and translational research. Application areas that will benefit include


clinical diagnostics, biopharmaceuticals, energy and chemicals, environmental science, food testing and agriculture, materials research, and proteomics. The suite will also serve as an Agilent instrument demonstration lab and showcase for customers to experience the company’s definitive workflow solutions. ‘Imperial College London plays a very


important role in advancing a deeper understanding of the world through their lab instruction and research,’ said Mike McMullen, Agilent president, and CEO. ‘We recognise the important contributions


made by university scientific research to solve real-life challenges from finding new ways to fight cancer, to ensuring the purity


of food, to solving major environmental issues. It is an honour for Agilent to support Imperial in building an advanced scientific measurement and analytical laboratory on their new White City Campus. ‘We value our partnership and look


forward to taking this important step together,’ McMullen added. Imperial’s President, professor Alice Gast


commented: ‘Imperial’s new partnership with Agilent is a significant development as we strengthen our industry collaborations. Agilent’s best-in-field equipment in the Molecular Sciences Research Hub at White City will catalyse forefront multidisciplinary research on societal challenges from understanding disease on a molecular level to developing clean sources of energy.’ The partnership between Imperial


and Agilent is expected to drive further collaborative projects to the benefit of both partners, and to move cutting-edge research forward. This collaboration further underlines


Agilent’s already extensive commitment in support of Academia through its wide range of academic programs and growing network of Agilent Centers of Excellence. Tony Cass, professor of chemical biology in the Department of Chemistry and Institute of Biomedical Engineering at Imperial, has been appointed director of the Agilent Measurement Suite.


LABORATORY INFORMATICS


Citoxlab Group to acquire Solvo Biotechnology


Citoxlab Group, which offers a range of preclinical and specialty services, has announced it attends to acquire Solvo Biotechnology, a CRO specialising in drug transporter studies and the assessment of Drug-Drug Interactions (DDI). The closing of this operation will


take place within the next month. Financial details were not disclosed. Founded in 1999, Solvo


Biotechnology is a specialist in the field of drug transporter research. A field that is growing rapidly as the investigation of the transport mechanisms becomes pivotal for drug development. Alongside metabolism data, a


thorough knowledge of the drug candidates’ transport is key to identifying potential DDI, in addition to developing an understanding of their pharmacokinetic, pharmacodynamic and safety profile. Transporter studies are a regulatory requirement for entering large clinical trials and then requesting a marketing authorisation from health regulatory agencies. Through this new acquisition,


Citoxlab reinforces its position in the non-clinical CRO field, with consolidated sales of $167 million (€136 million) and a staff of 1,300, spread over nine sites – France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas-City), Denmark (Copenhagen) and Hungary (Veszprém, and now Budapest and Szeged). Jean-Francois Le Bigot,


heterogeneous hardware developed within the LEGaTO project will be applied in three use cases; healthcare, Smart homes and cities and Machine Learning. Healthcare applications could benefit from


this project through a decrease in energy consumption in the healthcare sector and an increase in healthcare application resilience and security – both critical requirements. The project also aims to demonstrate


how this research can be used to develop programming simplification and energy savings through the use of the LEGaTO software–hardware framework for the Internet of Things (IoT), smart homes and smart cities applications. Sensitive sensor information and actuator instructions can be received and sent via the developed secure IoT gateway. The project software could be used to improve the energy efficiency of machine


www.scientific-computing.com | @scwmagazine


learning by employing accelerators and tuning the model architecture at runtime. LEGaTO is funded by the European Commission with a budget of more than €5 million over the next three years, beginning on 1 December 2017. The partners of the project are Barcelona


Supercomputing Center (BSC, Spain), Universität Bielefeld (UNIBI, Germany), Université de Neuchatel (UNINE, Switzerland), Chalmers Tekniska Högskola AB (CHALMERS, Sweden), Machine Intelligence Sweden AB (MIS, Sweden), Technische Universität Dresden (TUD, Germany), Christmann Informationstechnik + Medien GmbH & Co. KG (CHR, Germany), Helmholtz-Zentrum für Infektionsforschung GmbH (HZI, Germany), TECHNION – Israel Institute of Technology (TECHNION, Israel), Maxeler Technologies Limited (MAXELER, United Kingdom).


president and CEO of Citoxlab Group, said: ‘The acquisition of Solvo Biotechnology will allow us to offer the most elaborated in vitro Drug Metabolism and PharmacoKinetics (DMPK) services to our customers. ‘These are fully complementary with the in vivo DMPK studies we already provide from our sites in France, the US and Canada. As an example, using in vitro human hepatocytes, the assessment of transport and metabolism is possible at a very early stage of development. ‘These investigations are


increasingly included in the selection of lead candidates; in vitro inter-species comparisons now contribute significantly to the selection of the relevant species in safety studies.’


April/May 2018 Scientific Computing World 37


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40